Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

766
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
766
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

526
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
526
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

575
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
575
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

302
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
302
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

366
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
366
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.8K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply - Letter to the Editor: Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.

Shock (Augusta, Ga.)·2026
Same author

Clinical practices in general anaesthesia for caesarean section: A nationwide cross-sectional survey.

European journal of anaesthesiology and intensive care·2026
Same author

Reply - Letters to the Editor by Hübner, Berlot, Bottari et al.: Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.

Shock (Augusta, Ga.)·2026
Same author

Sex-specific molecular and cellular phenotypes during resolution of neuropathic pain in dorsal root ganglia.

Cell reports·2026
Same author

Association between preoperative hold time of SGLT2 inhibitors and postoperative blood ketone concentration: an interim analysis of a multicentre prospective cohort study.

British journal of anaesthesia·2026
Same author

Extraction and processing of intensive care chart data from a patient data management system.

Frontiers in digital health·2026

Related Experiment Video

Updated: Nov 23, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.7K

COVID-19 Induced Acute Respiratory Distress Syndrome-A Multicenter Observational Study.

Johannes Herrmann1, Elisabeth Hannah Adam2, Quirin Notz1

  • 1Department of Anesthesiology and Critical Care, University Hospital Würzburg, Julius-Maximilians-University Würzburg, Würzburg, Germany.

Frontiers in Medicine
|January 4, 2021
PubMed
Summary

Intensive care for severe COVID-19 acute respiratory distress syndrome (ARDS) patients showed a 65% survival rate. Standard ARDS treatments led to good outcomes, with no need for ICU triage.

Keywords:
ARDS (acute respiratory distress syndrome)COVID-19Germanyintensive care medicinepandemia

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.6K

Related Experiment Videos

Last Updated: Nov 23, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.7K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.6K

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pulmonology

Background:

  • COVID-19 mortality rates vary globally.
  • This study focuses on critically ill patients with COVID-19 induced ARDS requiring intensive care.

Purpose of the Study:

  • To report the characteristics, clinical course, and outcomes of COVID-19 patients with ARDS in German ICUs.
  • To evaluate the effectiveness of standard ARDS treatments in this population.

Main Methods:

  • Retrospective, observational, multicenter study in five German hospitals.
  • Inclusion of 106 patients admitted to the ICU between March 12 and May 4, 2020, with COVID-19 induced ARDS.
  • Data collection on patient characteristics, treatment, and outcomes.

Main Results:

  • Overall ICU survival rate was 65.0%.
  • Median ICU stay was 11 days, with mechanical ventilation for 9 days.
  • Older age, diabetes, and higher SOFA scores were associated with non-survival.

Conclusions:

  • Standard ARDS management in critically ill COVID-19 patients resulted in a favorable outcome.
  • The majority of patients did not receive specific antiviral or anti-inflammatory therapies.
  • Venovenous ECMO was used in 16.3% of cases; ICU triage was not required.